Inhibition of human cytomegalovirus protease No with monocyclic β-lactams
A new series of inhibitors of the cytomegalovirus protease is reported. We found that monocyclic β-lactams analogs are potent and selective inhibitors of the title protease.
References (8)
- et al.
J. Virol.
(1996)et al.J. Virol.
(1996)et al.Perspect. Drug Discov. Design
(1995) - et al.
Nature
(1996)et al.Nature
(1996)et al.Nature
(1996)et al.Cell
(1996)
Cited by (62)
Reassessing the putative molecular Target(s) of potent antitubercular 2-(Alkylsulfonyl)acetamides
2024, European Journal of Medicinal ChemistryC4-Phenylthio β-lactams: Effect of the chirality of the β-lactam ring on antimicrobial activity
2019, Bioorganic and Medicinal ChemistryCitation Excerpt :Based on our results, a possible explanation of the lack of substantial difference in the activity of the individual isomers of our compounds is that loss of thiophenol might occur in a concerted fashion along with β-lactam ring opening, a possible pathway suggested earlier.13 In all of the previous studies on structurally similar monocyclic β-lactams (with a leaving group at C4) as inhibitors of both mammalian15–17 and viral16,19 serine proteases, including structures carbamylated16–19 at the lactam nitrogen, the mechanism (proposed or experimentally determined) of enzyme inhibition involves lactam ring opening by the active site serine (covalent complex B, Scheme 3). If formed, either one of the enzyme complexes, enzyme form A, a noncovalent complex, and enzyme form B, a covalent complex (Scheme 3) should experience the chirality at C4.
Herpesvirus proteases: Structure, function, and inhibition
2017, Viral Proteases and Their InhibitorsNon-transpeptidase binding arylthioether β-lactams active against Mycobacterium tuberculosis and Moraxella catarrhalis
2015, Bioorganic and Medicinal Chemistry